Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.

doi:10.1158/1078-0432.CCR-25-2333

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2025

Ozawa Hiroki, Takahashi Kazuki, Motegi Tomoki, Jacobi Justine, Bhattarchya Atrayee, Shigeta Keisuke, Takamori Shinkichi, Onishi Mai, Luan Zhou, Fukuda Kazumasa, Ueno Akihisa, Kitago Minoru, Kawakubo Hirofumi, Kitagawa Yuko, Keith Dove, Muschler John, Sears Rosalie C, Long Mark D, Mancias Joseph D, Aguirre Andrew J, Kufe Donald

Abstract excerpt

PURPOSE: Treatment of pancreatic ductal adenocarcinoma (PDAC) has been advanced by the development of KRAS inhibitors. Despite this progress, PDAC invariably develop resistance to these agents through multiple mechanisms. In this study, we investigated the role of the oncogenic MUC1-C (M1C) protein in mediating the resistance of PDAC cells to KRAS inhibition. EXPERIMENTAL DESIGN: Three PDAC KRAS G12D-mutant cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mucin-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Drug Resistance, Neoplasm

Share to Immunoconjugates

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Transcription Factor RelA

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41086055
DOI: 10.1158/1078-0432.CCR-25-2333
PMCID: PMC12703357

Genes

KRAS
MUC1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.PMID 41086055Read ↗

Oncogenic Kras G12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 + T cells dependent mannerSemantic proximity Read ↗

Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer.Semantic proximity Read ↗

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitorsSemantic proximity Read ↗

Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts.Semantic proximity Read ↗

Resistance to the KRAS G12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET InhibitionSemantic proximity Read ↗

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Semantic proximity Read ↗

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis.Semantic proximity Read ↗

Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.